These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

589 related items for PubMed ID: 28478459

  • 1. Impact of Mild-to-Moderate Chronic Kidney Disease on One Year Outcomes after Percutaneous Coronary Intervention.
    Grandjean-Thomsen NL, Marley P, Shadbolt B, Farshid A.
    Nephron; 2017; 137(1):23-28. PubMed ID: 28478459
    [Abstract] [Full Text] [Related]

  • 2. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials.
    Baber U, Giustino G, Sartori S, Aquino M, Stefanini GG, Steg PG, Windecker S, Leon MB, Wijns W, Serruys PW, Valgimigli M, Stone GW, Dangas GD, Morice MC, Camenzind E, Weisz G, Smits PC, Kandzari D, Von Birgelen C, Mastoris I, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R.
    JACC Cardiovasc Interv; 2016 Jan 11; 9(1):28-38. PubMed ID: 26762908
    [Abstract] [Full Text] [Related]

  • 3. Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.
    Siddiqi OK, Smoot KJ, Dufour AB, Cho K, Young M, Gagnon DR, Ly S, Temiyasathit S, Faxon DP, Gaziano JM, Kinlay S.
    Heart; 2015 Oct 11; 101(19):1569-76. PubMed ID: 26209334
    [Abstract] [Full Text] [Related]

  • 4. The adverse long-term impact of renal impairment in patients undergoing percutaneous coronary intervention in the drug-eluting stent era.
    Appleby CE, Ivanov J, Lavi S, Mackie K, Horlick EM, Ing D, Overgaard CB, Seidelin PH, von Harsdorf R, Dzavík V.
    Circ Cardiovasc Interv; 2009 Aug 11; 2(4):309-16. PubMed ID: 20031733
    [Abstract] [Full Text] [Related]

  • 5. Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial.
    Crimi G, Leonardi S, Costa F, Adamo M, Ariotti S, Valgimigli M.
    Int J Cardiol; 2016 Jun 01; 212():110-7. PubMed ID: 27038714
    [Abstract] [Full Text] [Related]

  • 6. Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era: Pooled Analysis of the Korean Multicenter Drug-Eluting Stent Registry.
    Lee JM, Kang J, Lee E, Hwang D, Rhee TM, Park J, Kim HL, Lee SE, Han JK, Yang HM, Park KW, Na SH, Kang HJ, Koo BK, Kim HS.
    JACC Cardiovasc Interv; 2016 Oct 24; 9(20):2097-2109. PubMed ID: 27692820
    [Abstract] [Full Text] [Related]

  • 7. Impact of chronic kidney disease on long-term clinical outcomes after percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Kersting S, Grumann T, Hummel J, Hauschke D, Bode C, Hehrlein C.
    Crit Pathw Cardiol; 2012 Sep 24; 11(3):152-9. PubMed ID: 22825536
    [Abstract] [Full Text] [Related]

  • 8. Increased cystatin C levels as a risk factor of cardiovascular events in patients with preserved estimated glomerular filtration rate after elective percutaneous coronary intervention with drug-eluting stents.
    Sai E, Shimada K, Miyauchi K, Masaki Y, Kojima T, Miyazaki T, Kurata T, Ogita M, Tsuboi S, Yoshihara T, Miyazaki T, Ohsaka A, Daida H.
    Heart Vessels; 2016 May 24; 31(5):694-701. PubMed ID: 25863806
    [Abstract] [Full Text] [Related]

  • 9. Impact of chronic kidney disease on patients with unprotected left main coronary artery disease treated with coronary artery bypass grafting or drug-eluting stents.
    Pan Y, Qiu Q, Chen F, Li X, Yu X, Luo Y, Li Q, He J, Gao Y, Zhang X, Ren X.
    Coron Artery Dis; 2016 Nov 24; 27(7):535-42. PubMed ID: 27269882
    [Abstract] [Full Text] [Related]

  • 10. Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney disease.
    Wanitschek M, Pfisterer M, Hvelplund A, De Servi S, Bertel O, Jeger R, Rickenbacher P, Iversen A, Jensen JS, Galatius S, Kaiser C, Alber H, BASKET-PROVE Investigators.
    Int J Cardiol; 2013 Oct 03; 168(3):2381-8. PubMed ID: 23453439
    [Abstract] [Full Text] [Related]

  • 11. Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents.
    Miao Y, Yu-Jie Z, Zhi-Jian W, Dong-Mei S, Yu-Yang L, Ying-Xin Z, Fei G, Shi-Wei Y, De-An J.
    Catheter Cardiovasc Interv; 2012 Sep 01; 80(3):361-7. PubMed ID: 22419375
    [Abstract] [Full Text] [Related]

  • 12. Impact of severity of renal dysfunction on determinants of in-hospital mortality among patients undergoing percutaneous coronary intervention.
    Parikh PB, Jeremias A, Naidu SS, Brener SJ, Lima F, Shlofmitz RA, Pappas T, Marzo KP, Gruberg L.
    Catheter Cardiovasc Interv; 2012 Sep 01; 80(3):352-7. PubMed ID: 22566286
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Perioperative and long-term impact of chronic kidney disease on carotid artery interventions.
    Klarin D, Lancaster RT, Ergul E, Bertges D, Goodney P, Schermerhorn ML, Cambria RP, Patel VI, Vascular Study Group of New England.
    J Vasc Surg; 2016 Nov 01; 64(5):1295-1302. PubMed ID: 27776697
    [Abstract] [Full Text] [Related]

  • 15. Impact of renal insufficiency on safety and efficacy of drug-eluting stents compared to bare-metal stents at 6 years.
    Simsek C, Magro M, Boersma E, Onuma Y, Nauta S, Valstar G, van Geuns RJ, van der Giessen W, van Domburg R, Serruys P, Interventional Cardiologists of Thoraxcenter.
    Catheter Cardiovasc Interv; 2012 Jul 01; 80(1):18-26. PubMed ID: 21735520
    [Abstract] [Full Text] [Related]

  • 16. Five-year mortality outcomes in patients with chronic kidney disease undergoing percutaneous coronary intervention.
    Patel AD, Ibrahim M, Swaminathan RV, Minhas IU, Kim LK, Venkatesh P, Feldman DN, Minutello RM, Bergman GW, Wong SC, Singh HS.
    Catheter Cardiovasc Interv; 2017 Mar 01; 89(4):E124-E132. PubMed ID: 27519355
    [Abstract] [Full Text] [Related]

  • 17. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
    Puymirat E, Mangiacapra F, Peace A, Ntarladimas Y, Conte M, Bartunek J, Vanderheyden M, Wijns W, de Bruyne B, Barbato E.
    Arch Cardiovasc Dis; 2013 Nov 01; 106(11):554-61. PubMed ID: 24231052
    [Abstract] [Full Text] [Related]

  • 18. Revascularization in Patients With Multivessel Coronary Artery Disease and Chronic Kidney Disease: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery.
    Bangalore S, Guo Y, Samadashvili Z, Blecker S, Xu J, Hannan EL.
    J Am Coll Cardiol; 2015 Sep 15; 66(11):1209-1220. PubMed ID: 26361150
    [Abstract] [Full Text] [Related]

  • 19. The anatomic- and clinical-based NERS (new risk stratification) score II to predict clinical outcomes after stenting unprotected left main coronary artery disease: results from a multicenter, prospective, registry study.
    Chen SL, Han YL, Zhang YJ, Ye F, Liu HW, Zhang JJ, Xu B, Jiang TM, Zhou YJ, Lv SZ.
    JACC Cardiovasc Interv; 2013 Dec 15; 6(12):1233-41. PubMed ID: 24239199
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular outcomes following percutaneous coronary intervention with drug-eluting balloons in chronic kidney disease: a retrospective analysis.
    Jonas M, Kagan M, Sella G, Haberman D, Chernin G.
    BMC Nephrol; 2020 Oct 23; 21(1):445. PubMed ID: 33097001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.